title: Successful non-T cell-depleted HLA haplo-identical three-loci mismatched hematopoietic stem cell transplantation from mother to son based on the feto-maternal microchimerism in chronic myelogenous leukemia.
abstract: A 17-year-old male with chronic myelogenous leukemia in blast crisis received a non-T cell-depleted (TCD) HLA haplo-identical three-loci mismatched hematopoietic stem cell transplant (HSCT) from his mother. Long-term feto-maternal microchimerism was detected by nested polymerase chain reaction with sequence-specific primer typing. The post-transplantation prophylaxis against graft-versus-host disease (GVHD) was tacrolimus with minidose methotrexate. Sustained engraftment was obtained. Acute GVHD (grade 2) developed, but improved rapidly. Bone marrow aspiration on day 120 showed complete remission. Non-TCD HLA haplo-identical HSCT based on feto-maternal microchimerism might be feasible and has important implications in the selection of alternative family donors in HSCT.
authors.affiliation: Second Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Ochiai
authors.forename: C
authors.initials: C
authors.lastname: Shimazaki
authors.forename: S
authors.initials: S
authors.lastname: Fuchida
authors.forename: A
authors.initials: A
authors.lastname: Okano
authors.forename: T
authors.initials: T
authors.lastname: Sumikuma
authors.forename: E
authors.initials: E
authors.lastname: Ashihara
authors.forename: T
authors.initials: T
authors.lastname: Inaba
authors.forename: N
authors.initials: N
authors.lastname: Fujita
authors.forename: E
authors.initials: E
authors.lastname: Maruya
authors.forename: M
authors.initials: M
authors.lastname: Nakagawa
mesh_terms: D000293:Adolescent; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000517:prevention & control; D006239:Haplotypes; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006648:Histocompatibility; D006650:Histocompatibility Testing; D006801:Humans; D007108:Immune Tolerance; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000628:therapy*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D009679:Nuclear Family; D016559:Tacrolimus / Q000627:therapeutic use; D018183:Transplantation Chimera; D016896:Treatment Outcome
chemical_list: D016559:Tacrolimus; D008727:Methotrexate